Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide nasal spray - Marinomed Biotechnologie

Next Previous
Drug Profile

Budesonide nasal spray - Marinomed Biotechnologie

Alternative Names: Budesolv - Marinomed Biotechnologie; MAM-1004-1

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Marinomed Biotechnologie
  • Class Alcohols; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Dioxoles; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Allergic rhinitis

Highest Development Phases

  • Phase III Allergic rhinitis

Most Recent Events

  • 23 Sep 2025 company addition req sent for Luoxin PharmaceuticalBudesonide nasal spray - Marinomed Biotechnologie is available for licensing in World (excluding China) as of 23 Sep 2025. https://www.marinomed.com/en/ and https://www.marinomed.com/fileadmin/01_Marinomed/03_Partnering/01_Business_Development/20250211_Budesolv_teaser.pdf
  • 28 Feb 2025 Efficacy data from a phase-III trial in Allergic rhinitis released by Marinomed Biotechnologie

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top